Tandem Diabetes (TNDM) announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology to advance research and development efforts on fully automated closed-loop insulin delivery systems. The collaboration will expand on Tandem’s ongoing research into the advancement of automated closed-loop insulin delivery technology, and will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem’s next-generation AID systems. Tandem will provide research funding, technology, and supplies to the University of Virginia during the agreement term for diabetes-centered research and potential clinical studies.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes, Insulet views Positive at OTR Global after checks
- Tandem Diabetes price target lowered to $50 from $57 at Citi
- Morgan Stanley upgrades ‘too cheap’ Tandem Diabetes to Overweight
- Tandem Diabetes upgraded to Overweight from Equal Weight at Morgan Stanley
- Tandem Diabetes price target raised to $60 from $58 at Barclays